Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus



Imeglimin is the first in a new class of oral antidiabetic agents, the glimins, currently in development to improve glycemic control in patients with type 2 diabetes mellitus. A thorough QT study was conducted to establish electrophysiological effects of therapeutic and supratherapeutic doses of imeglimin on cardiac repolarization.


In this randomized, double-blind, four-period, placebo and active controlled crossover study, healthy subjects were administered a single dose of imeglimin 2250 mg, imeglimin 6000 mg, moxifloxacin 400 mg, and placebo. 12-Lead Holter ECGs were recorded from 1 h before dosing until at least 24 h after each dose. This study was performed at a single-center inpatient clinical pharmacology unit.


The upper bound of the two-sided 90% confidence interval for time-matched, placebo-subtracted, baseline-adjusted QTc intervals (ΔΔQTcF) did not exceed the regulatory threshold of 10 ms in any of the imeglimin dose groups. There were no QTcF values above 500 ms nor changes from pre-dose in QTcF above 60 ms in the imeglimin groups. Imeglimin did not exert a relevant effect on heart rate and PR or QRS intervals. Assay sensitivity was demonstrated by the effect of moxifloxacin 400 mg, with a lower bound two-sided 90% confidence interval for ΔΔQTcF of 10.6 ms.


This thorough QT study demonstrated that therapeutic and supratherapeutic exposures of imeglimin did not induce a QT/QTc prolongation with a strong confidence as evidenced by the assay sensitivity.

Trial registration number/date

NCT02924337/ October 5, 2016

This is a preview of subscription content, log in to check access.

Fig. 1
Fig. 2
Fig. 3


  1. 1.

    Matthaei S, Stumvoll M, Kellerer M, Haring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocrine reviews 21(6):585–618. https://doi.org/10.1210/edrv.21.6.0413

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Meier JJ, Butler PC (2005) Insulin secretion. In: Endocrinologyed. Elservier Saunders.

  3. 3.

    (1998) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet (London, England) 352(9131):837–853

  4. 4.

    WHO (2016) Global report on Diabetes

  5. 5.

    The Japan Diabetes Society (2013) Evidence-based practice guidelines for diabetes in Japan

  6. 6.

    Pirags V, Lebovitz H, Fouqueray P (2012) Imeglimin, a novel glimin oral antidiabetic, exhibits a good efficacy and safety profile in type 2 diabetic patients. Diabetes Obes Metab 14(9):852–858. https://doi.org/10.1111/j.1463-1326.2012.01611.x

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Vial G, Chauvin MA, Bendridi N, Durand A, Meugnier E, Madec AM, Bernoud-Hubac N, Pais de Barros JP, Fontaine É, Acquaviva C, Hallakou-Bozec S, Bolze S, Vidal H, Rieusset J (2015) Imeglimin normalizes glucose tolerance and insulin sensitivity and improves mitochondrial function in liver of a high-fat, high-sucrose diet mice model. Diabetes 64(6):2254–2264. https://doi.org/10.2337/db14-1220

    CAS  Article  PubMed  Google Scholar 

  8. 8.

    Pacini G, Mari A, Fouqueray P, Bolze S, Roden M (2015) Imeglimin increases glucose-dependent insulin secretion and improves β-cell function in patients with type 2 diabetes. Diabetes Obes Metab 17(6):541–545. https://doi.org/10.1111/dom.12452

    CAS  Article  PubMed  Google Scholar 

  9. 9.

    Detaille D, Vial G, Borel AL, Cottet-Rouselle C, Hallakou-Bozec S, Bolze S, Fouqueray P, Fontaine E (2016) Imeglimin prevents human endothelial cell death by inhibiting mitochondrial permeability transition without inhibiting mitochondrial respiration. Cell death discovery 2:15072. https://doi.org/10.1038/cddiscovery.2015.72

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  10. 10.

    Bolze S (2017) Safety, tolerability and pharmacokinetics of Imeglimin in healthy Japanese subjects. Asian Association for the Study of Diabetes (AASD), Nagoya, 19-20 May

  11. 11.

    Fouqueray P (2015) Dose ranging-study to determine the optimum dose for imeglimin, a novel treatment for type 2 diabetes.American Diabetes Association (ADA), Boston, 5-9 June

  12. 12.

    Dubourg J (2017) Imeglimin monotherapy in Japanese patients with type 2 diabetes: results from a randomised, 24-week, double-blind, placebo-controlled, phase IIb trial. European Association for the Study of Diabetes (EASD), Lisbon, 11-15 September

  13. 13.

    Dubourg J (2019) Clinical evidence to support the safety and efficacy of imeglimin in various population of patients with type 2 diabetes. European Association for the Study of Diabetes (EASD), Barcelona, 16-20 September

  14. 14.

    ICH (2005) International conference on harmonisation; guidance on E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs; availability. Notice. Federal register 70(202):61134–61135

    Google Scholar 

  15. 15.

    (1997) World Medical Association declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. Jama 277(11):925–926

Download references


This study was sponsored by Poxel. The authors were fully responsible for all content and editorial decisions, were involved at all stages of manuscript development, and have approved the final version.

Author information




JD contributed to the interpretation of data and drafted and edited the report. SP, MF, SB, PV, and PF contributed to the study design and interpretation of data and reviewed the report. All authors read the manuscript critically and approved the submitted version.

Corresponding author

Correspondence to Julie Dubourg.

Ethics declarations

This clinical trial was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines [15] and was approved by an Independent Ethics Committee/Institutional Review Board (Office for Research Ethics Committees Northern Ireland - ORECNI). All participants provided written informed consent prior to any trial-related activities.

Conflict of interest

JD, SP, SB, and PF are employees of Poxel. MF is an employee of Phinc development. PV is an employee of Banook Group.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Dubourg, J., Perrimond-Dauchy, S., Felices, M. et al. Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus. Eur J Clin Pharmacol (2020). https://doi.org/10.1007/s00228-020-02929-6

Download citation


  • Imeglimin
  • QT interval
  • Thorough QT study
  • Type 2 diabetes mellitus